Stockreport

Relay Therapeutics: Tapping Into An Unmet Need At A High Price Tag [Seeking Alpha]

Relay Therapeutics, Inc.  (RLAY) 
PDF Their lead agent, lirafugratinib, is being tested for intrahepatic cholangiocarcinoma and has shown promising results in early clinical studies. The company also has [Read more]